

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: *Kisilevsky, et al.*

Serial No.: 09/970,148

Filed: October 2, 2001

For: *Methods and Compositions to Treat
Glycosaminoglycan-Associated Molecular
Interactions*

Attorney Docket No.: NCI-043CN

Group Art Unit: 1654

Examiner: Jeffrey E. Russel

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this correspondence is being transmitted by facsimile in accordance with 37 C.F.R. §1.8 to Commissioner for Patents, Washington, D.C. 20231, to the attention of the examiner captioned above, on the date set forth below:	
<u>March 14, 2003</u> Date of Signature and Transmission	By: <u>[Signature]</u> Theodore A. West, Reg. No. 47,202 Agent for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration.

The present application is a Continuation Application of U.S. Serial No. 09/362505, filed July 27, 1999 (Atty. Docket No. NCI-043). All references listed on the enclosed PTO Form 1449 (7 pages) have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 C.F.R. §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

Application No. 09/970,148
By: Kisilevsky, *et al.*

- 2 -


Examiner: J E. Russel
Art Unit: 1654

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. §1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By: _____


Theodore R. West
Reg. No. 47,202
28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214

Date: _____

March 14, 2003